Linked Life Data

9563125

Source:http://linkedlifedata.com/resource/pubmed/id/9563125

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
1998-6-30
pubmed:abstractText
Androgenablation is the therapy of choice for the treatment of advanced and metastatic prostate cancer. However, in more than half of the patients the disease will ultimately progress within 2 years. Intermittent androgenablation through medical castration maintains the apoptotic potential. By periodically changing phases on and off treatment the quality of life of the patients is improved. Apart from reduced toxicity treatment costs are lowered and tumor progression is possibly delayed. In how far survival is influenced is presently not clear and remains to be evaluated in further clinical trials.
pubmed:language
ger
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
0340-2592
pubmed:author
pubmed:issnType
Print
pubmed:volume
37
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
153-5
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed:year
1998
pubmed:articleTitle
[Intermittent versus continuous androgen blockade].
pubmed:affiliation
Urologische Klinik, Universitätsklinikum, RWTH Aachen.
pubmed:publicationType
Journal Article, English Abstract, Review